Nvidia Shares Hit Again After RBC Lowers Price Target

RBC sees lower selling prices for NVDA gaming chips

Dec 27, 2018 at 3:17 PM
facebook X logo linkedin


U.S. stocks are lower following Wednesday's historic rally. Three names in the news are GPU expert Nvidia Corporation (NASDAQ:NVDA), online services provider Live Ventures Inc (NASDAQ:LIVE), and drugmaker BioXcel Therapeutics Inc (NASDAQ:BTAI). Here's what you need to know about shares of NVDA, LIVE, and BTAI today.

RBC Lowers NVDA Price Target

NVDA stock is trading down 5% at $126.47 after a price-target cut to $200 from $230 at RBC. The brokerage firm apparently sees potential pricing headwinds around Nvidia's GTX 1070 gaming chip for 2019, which it expects to keep the shares range bound. The equity has lost more than half its value in the past three months, touching an annual low of $124.46 yesterday.

Short sellers have certainly taken aim at the chipmaker. In the last two reporting periods, short interest rose by 45%, putting almost 18 million shares in the hands of short sellers -- the most since June 2017.

2018 Financials Smack LIVE Stock

Live Ventures stock is getting hammered after the company revealed its full-year financial results for 2018. After jumping out of the gate, the shares have fallen 9.8% to trade at $7.89, plummeting below recent support from the 20-day moving average. This continues the security's long-term descent, as it was trading around $20 this time last year. In fact, short sellers have been in profit-taking mode on LIVE since March, and now hold just 1.7% of the total float.

FDA Designation Sends BTAI Soaring

BioXcel Therapeutics' acute agitation treatment, BXCL501, was given "fast track" status from the Food and Drug Administration (FDA), sending the stock up 70% at $4.09. The shares -- which began trading publicly at $11 back in March -- hit an all-time low of $2.41 yesterday, and topped out near their 50-day moving average earlier.

We'll see if any analysts downwardly revise their outlooks on BTAI stock, considering this long-term technical weakness. For now, all five brokerage firms in coverage recommend buying the biopharma concern, and the average price target stands as high as $18.20.

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI